Shield Therapeutics Plc has raised £32.5 million in an initial public offering of shares on the AIM market of the London Stock Exchange in the wake of a positive opinion from the European Medicines Agency for its drug for iron deficiency anaemia. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
